Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism

International Urology and Nephrology

Volumn 36, Issue 1, 2003, Pages 113-118

  Baskin, Esra ^a   Ozen, Seza ^b   Karçaaltincaba, Musturay ^b   Besbas, Nesrin ^b   Saatci, Umit ^a   Düzova, Ali ^b   Isik Agras, Pinar ^a   Haliloglu, Mithat ^b   Bakkaloglu, Aysin ^b  

^a BASKENT UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Allograft; Bone mineral density; Calcitriol; Dialysis; Renal osteodystrophy

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; PARATHYROID HORMONE;

ADOLESCENT; ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; LONG TERM CARE; MALE; OSTEOPENIA; PROSPECTIVE STUDY; SCORING SYSTEM; SECONDARY HYPERPARATHYROIDISM; STATISTICAL SIGNIFICANCE;

EID: 3042767218     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:UROL.0000032691.62102.1d     Document Type: Article

References (25)

1. Levis S, Altman R. Bone densitometry. Clinical considerations. Arthritis Rheum 1998; 41: 577-587.
2. Johnston CC, Slemenda CW, Melton LJ. Clinical use of bone densitometry. N Engl J Med 1991; 324: 1105-1109.
3. Stein MS, Packham DK, Ebeling PR, Wark JD, Becker GJ. Prevalence and risk factors for osteopenia in dialysis patients. Am J Kidney Dis 1996; 28: 515-522.
4. McCarthy JT, Kumar R. Renal osteodystrophy. Endocrinol Metab Clin North Am 1990; 19: 65-93.
5. Ritz E, Matthias S, Seidel A, Reichel H, Szabo A, Horl WH. Disturbed calcium metabolism in renal failure. Pathogenesis and therapeutic strategies. Kidney Int 1992; 42(Suppl 38): S37-S42.
6. Coburn JW. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 1990; 38(Suppl 29): S54-S61.
7. Malluche HH, Faugere MC. Effects of 1,25 (OH)2 D3 administration on bone in patients with renal failure. Kidney Int 1990; 38 (Suppl 29): S48-S53.
8. Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour JP. Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney Int 1994; 45: 245-252.
9. Huraib S, Abu-Aisha H, Abed J, Al Wakeel J, Al Desouki M, Memon N. Long-term effect of intravenous calcitriol on the treatment of severe hyperparathyroidsm, parathyroid gland mass and bone mineral density in haemodialysis patients. Am J Nephrol 1997; 17: 118-123.
10. Feinfeld DA, Sherwood LM. Parathyroid hormone and 1,25 (OH)2 D3 in chronic renal failure. Kidney Int 1988; 33: 1049-1058.
11. Moe S, Yu B, Sprague S. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis 1993; 22: 300-307.
12. Copley J, Hui S, Leepman S, Slemenda C, Johnson C. Longitudinal study of bone mass in end-stage renal disease patients: effects of parathyroidectomy for renal osteodystrophy. J Bone Miner Res 1993; 8: 415-422.
13. Stehman-Breen CO, Sherrard D, Walker A, Sadler R, Alem A, Lindberg J. Racial differences in bone mineral density and bone loss among end-stage renal disease patients. Am J Kidney Dis 1999; 33: 941-946.
14. Cheung AK, Minolagas SC, Catherwood BD et al. Determinants of serum 1,25 (OH)2 D levels in renal disease. Kidney Int 1983; 24: 104.
15. Dressler R, Laut J, Lynn RI, Ginsberg N. Long-term high dose intravenous calcitriol therapy in end-stage renal disease patients with severe secondary hyperparathyroidism. Clin Nephrol 1995; 43: 324-331.
16. Rodriguez M, Felsenfeld AJ, Williams C, Pederson JA, Llach F. The effect of long-term intravenous intravenous calcitriol administration on parathyroid function in haemodialysis patients. J Am Soc Nephrol 1991; 2: 1014-1020.
17. Sprague SM, Moe SM. Safety and efficacy of long-term treatment of secondary hyperparathyroidism. Am J Kidney Dis 1992; 19: 532-539.
18. Przedlacki J, Manelius J, Huttunen K. Bone mineral density evaluated by dual-energy X-ray absorptiometry after one-year treatment with calcitriol started in the predialysis phase of chronic renal failure. Nephron 1995; 69: 433-437.
19. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Brownwer W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992; 7: 633-638.
20. Melton LJ, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res 1993; 8: 1227-1233.
21. Boling E, Primavera C, Friedman G et al. Non-invasive measurements of bone mass in adult renal osteodystrophy. Bone 1993; 14: 409-413.
22. Hutchison A, Whitehouse R, Boulton H et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071-1077.
23. Harris M, Nguyen TV, Howard GM, Kelly PJ, Eismann JA. Genetic and enviromental correlations between bone formation and bone mineral density: a twin study. Bone 1998; 22: 141-145.
24. Yokoyama K, Shigematsu T, Tsukada T et al. Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney Int 1998; 53: 454-458.
25. Karkoszka H, Chudek J, Strzelczyk P et al. Does the vitamin D receptor genotype predict bone mineral loss in haemodialysed patients. Nephrol Dial Transplant 1998; 13: 2077-2080.